Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients.

Hirano, T; Nohtomi, K; Nakanishi, N; Watanabe, T; Hyodo, T; Taira, T

Hirano, T; Nohtomi, K; Nakanishi, N; Watanabe, T; Hyodo, T; Taira, T.

Affiliation

Hirano T; Department of Diabetes, Metabolism and Endocrinology, Showa University School of Medicine, Tokyo, Japan. hirano@med.showa-u.ac.jp

Clin Nephrol ; 74(4): 282-7, 2010 Oct.

Article in En | MEDLINE | ID: mdl-20875380

Subject(s)

Anticholesteremic Agents/pharmacology; Azetidines/pharmacology; Lipoproteins, HDL3/analysis; Renal Dialysis; Serum Amyloid A Protein/analysis; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I/blood; Cholesterol, HDL/blood; Cholesterol, LDL/blood; Ezetimibe; Female; Humans; Male; Middle Aged

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Azetidines / Serum Amyloid A Protein / Renal Dialysis / Lipoproteins, HDL3 / Anticholesteremic Agents Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Nephrol Year: 2010 Type: Article Affiliation country: Japan

Search on Google

XML

PubMed Links